📖
The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia
Guillaume Olombel, Estelle Guérin, Julien Guy, Jean-Yves Perrot, Florence Dumezy, Adrienne de Labarthe, Jean-Noël Bastie, O. Legrand, Emmanuel Raffoux, Adriana Plesa, Oriane Wagner-Ballon, Edouard Cornet, Véronique Salaun, Claude Preudhomme, Xavier Thomas, Cécile Pautas, Sylvain Chantepie, Pascal Turlure, Sylvie Castaigne, Hervé Dombret, Jean Feuillard

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia

Science & Mathematics Published 2016 Verification Pending

Overview & Synopsis

Gemtuzumab ozogamicin (GO) is an immunoconjugate, combining an anti-CD33 monoclonal antibody to calicheamicin, a highly cytotoxic antibiotic. First developed as single agent in adults with relapsed acute myeloid leukemia (AML), it was then evaluated in combination with chemotherapy in newly diagnosed patients. In the randomized Acute Leukemia French Association (ALFA)–0701 study, we reported that sequential administration of a lower dose of GO allowed the safe delivery of a high cumulative dose associated with a substantial improvement in patient outcome. A recent meta-analysis has confirmed that adding GO to chemotherapy may provide a survival advantage in patients without adverse cytogenetic characteristics. However, these results were obtained regardless of the level of blast CD33 expression. In vitro, a clear relationship between CD33 expression and GO efficacy has nevertheless been shown. In vivo, contradictory results have been reported so far. No impact was found when CD33 expression was evaluated as a continuous covariable or using a 20% cutoff. Higher response rates were nevertheless reported for patients with CD33+ expression ≥98% in 1 phase 2 study or when showing CD33 expression as mean fluorescence intensity (MFI) using an isotype antibody as control. To further evaluate the impact of CD33 expression on GO treatment effect, we retrospectively analyzed the results of the ALFA-0701 study.

Indexed from repository: HAL Open Science (hal.science)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia
Author / Organization Guillaume Olombel, Estelle Guérin, Julien Guy, Jean-Yves Perrot, Florence Dumezy, Adrienne de Labarthe, Jean-Noël Bastie, O. Legrand, Emmanuel Raffoux, Adriana Plesa, Oriane Wagner-Ballon, Edouard Cornet, Véronique Salaun, Claude Preudhomme, Xavier Thomas, Cécile Pautas, Sylvain Chantepie, Pascal Turlure, Sylvie Castaigne, Hervé Dombret, Jean Feuillard
Subject & Discipline Multidisciplinary Academic Open Research
Categories Science & Mathematics
Publication Year 2016
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website HAL Open Science (hal.science)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-206519
Original Source Link Visit Source Page on hal.science »